Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 11, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification of share transactions and does not contain financial performance data.
Material Changes and Transactions
The filing details specific share movements executed by the GlaxoSmithKline Employee Trust ("GSK Trust") on behalf of employee incentive plans:
- May 9, 2006: Transfer of 158,125 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- May 10, 2006: Transfer of 584,286 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- May 10, 2006: Sale of 775 Ordinary Shares on behalf of participants in the SmithKline Beecham Mid-Term Incentive Plan at GBP 15.57 per share.
- May 10, 2006: Transfer of 1,137 Ordinary Shares to participants in the SmithKline Beecham Mid-Term Incentive Plan.
Three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) hold interests in the GSK Trust as potential beneficiaries alongside other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of the aforementioned share transactions under Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- Verify the total number of shares transferred to the SmithKline Beecham Employee Share Option Plan 1991 (742,411 shares total across two dates).
- Confirm the sale price of GBP 15.57 per share for the Mid-Term Incentive Plan transaction.
- Note that the GSK Trust is a discretionary trust for current and former employees, creating indirect interests for specific directors.
- Understand that this filing contains no financial performance metrics or strategic outlook.